5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 19.11▲ | 18.51▲ | 18.28▲ | 17.94▲ | 17.07▲ |
MA10 | 18.84▲ | 18.24▲ | 18.20▲ | 17.16▲ | 16.44▲ |
MA20 | 18.43▲ | 18.15▲ | 17.80▲ | 17.09▲ | 22.82▼ |
MA50 | 18.27▲ | 17.64▲ | 17.45▲ | 16.31▲ | 57.60▼ |
MA100 | 17.86▲ | 17.18▲ | 16.76▲ | 21.94▼ | 1,079.30▼ |
MA200 | 17.70▲ | 16.91▲ | 18.95▲ | 23.82▼ | 7,545.00▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.105▲ | 0.079▲ | 0.088▲ | 0.257▲ | 13.384▲ |
RSI | 68.855▲ | 67.702▲ | 66.775▲ | 56.153▲ | 36.389▼ |
STOCH | 92.352▲ | 51.406 | 54.492 | 78.656 | 31.984 |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -0.201▲ | -75.689▼ |
CCI | 92.877 | 197.300▲ | 203.451▲ | 152.106▲ | 4.174 |
Tuesday, April 29, 2025 06:05 AM
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development ...
|
Monday, April 28, 2025 05:00 PM
1 Day TNXP 2.17% DJIA 0.75% Russell 2K 0.56% Health Care/Life Sciences -0.50% ...
|
Thursday, April 24, 2025 04:55 AM
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
02/05/25 | 18.70 | 19.30 | 18.635 | 19.29 | 216,202 |
01/05/25 | 18.211 | 18.95 | 17.5963 | 18.04 | 517,323 |
30/04/25 | 17.15 | 18.2551 | 16.68 | 18.01 | 606,911 |
29/04/25 | 17.13 | 17.93 | 17.05 | 17.33 | 454,495 |
28/04/25 | 17.49 | 17.8436 | 16.70 | 17.03 | 515,068 |
25/04/25 | 17.05 | 18.74 | 16.83 | 17.82 | 808,850 |
24/04/25 | 17.57 | 18.5385 | 16.782 | 17.19 | 731,267 |
23/04/25 | 15.47 | 17.65 | 15.3825 | 17.02 | 853,815 |
22/04/25 | 14.80 | 15.075 | 14.35 | 14.96 | 453,735 |
21/04/25 | 15.53 | 15.5745 | 14.33 | 14.96 | 559,846 |
|
|
||||
|
|
||||
|
|